ilmscore | Prediction Details
"With two complexes and high value launches. Pristum and Semaglotite. By the end of FY26, this could offset the decline in G Rev Limit and boost revenue."
By Groww | June 25, 2025 | Pending
From video
3 Stocks With Better Fundamentals Than Their Valuation 00:11:47 - 00:11:56
Interpreted Prediction
Natco Pharma's new high-value product launches, Pristum and Semaglotite, could offset the revenue decline from the G Rev Limit patent expiry by the end of FY26.

Prediction Details

Ticker
NATCOPHARM

Comments

Be the first to share your thoughts.

Like this prediction?

Join to make your opinion count.